Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell Patents (Class 424/152.1)
-
Patent number: 8557244Abstract: This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.Type: GrantFiled: July 28, 2000Date of Patent: October 15, 2013Assignee: Biogen Idec Inc.Inventors: Christine White, Antonio Grillo-Lopez
-
Publication number: 20130259872Abstract: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFN?. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFN?.Type: ApplicationFiled: June 7, 2013Publication date: October 3, 2013Inventors: Yumiko Kamogawa, Minkwon Cho, Naoko Arai, Koji Ishida
-
Publication number: 20130251711Abstract: Compositions comprising compounds that neutralize NK cell inhibitory receptors and methods of using such compositions in the treatment of hematological malignancies are provided.Type: ApplicationFiled: November 22, 2011Publication date: September 26, 2013Applicant: INNATE PHARMA SAInventors: Pascale Andre, Renaud Buffet, Marcel Rozencweig, Jerome Tiollier
-
Publication number: 20130251675Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: February 23, 2013Publication date: September 26, 2013Applicant: STEMNION, INC.Inventors: Richard A Banas, Catherine J. Trumpower
-
Publication number: 20130243785Abstract: A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techniques, such as ultrasound and binding with an anti-AGE antibody, may be used to identify and remove the AGE-modified cells.Type: ApplicationFiled: September 27, 2011Publication date: September 19, 2013Inventor: Lewis Gruber
-
Publication number: 20130236451Abstract: Antibodies directed to the C-terminal side of ?-amyloid peptide and methods of using these antibodies for diagnosing and treatment of Alzheimer's disease and A? peptide associated diseases are described.Type: ApplicationFiled: February 14, 2013Publication date: September 12, 2013Applicant: RINAT NEUROSCIENCE CORP.Inventors: Arnon ROSENTHAL, Jaume PONS, Wei-Hsien HO
-
Patent number: 8529901Abstract: This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.Type: GrantFiled: June 4, 2008Date of Patent: September 10, 2013Assignee: Hoffmann-La Roche, Inc.Inventors: Max Hasmann, Helmut Lenz, Werner Scheuer
-
Patent number: 8530627Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: GrantFiled: July 3, 2008Date of Patent: September 10, 2013Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri
-
Publication number: 20130232589Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.Type: ApplicationFiled: April 24, 2013Publication date: September 5, 2013Applicant: diaDexus, Inc.Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
-
Patent number: 8524867Abstract: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.Type: GrantFiled: August 14, 2007Date of Patent: September 3, 2013Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, John O. Richards, Eugene Alexander Zhukovsky
-
Patent number: 8513028Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.Type: GrantFiled: May 8, 2007Date of Patent: August 20, 2013Assignee: Creagene Inc.Inventors: Jin Ah Jang, Dae Seog Lim, Hyun Soo Lee, Yong Soo Bae
-
Patent number: 8512705Abstract: The invention relates to binding compounds that specifically bind to human TSLP, as well as uses thereof, e.g., in the treatment of inflammatory disorders.Type: GrantFiled: June 25, 2012Date of Patent: August 20, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Leonard G. Presta, Rene de Waal Malefyt
-
Patent number: 8506959Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: GrantFiled: July 19, 2005Date of Patent: August 13, 2013Assignees: Neotope Biosciences Limited, The Regents of the University of CaliforniaInventors: Dale B. Schenk, Eliezer Masliah, Manuel Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
-
Publication number: 20130202527Abstract: The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies for the treatment of cancer (e.g., renal and ovarian cancer). In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: ApplicationFiled: April 15, 2013Publication date: August 8, 2013Applicant: Celldex Therapeutics, Inc.Inventor: Celldex Therapeutics, Inc.
-
Patent number: 8501427Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.Type: GrantFiled: January 23, 2008Date of Patent: August 6, 2013Assignee: University College Cardiff Consultants LimitedInventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
-
Publication number: 20130195761Abstract: Compositions comprising antibodies raised against CAP37 and isoforms thereof, along with antigen binding fragments thereof, are disclosed. These compositions have many uses, such as in detection of CAP37 and as an early detection marker for various disease conditions. In addition, the compositions may be used therapeutically to inhibit, mitigate, or modulate certain cellular activities involving CAP37 or to monitor a disease progression or the success of a disease treatment.Type: ApplicationFiled: March 15, 2013Publication date: August 1, 2013Applicant: The Board of Regents of the University of OklahomaInventors: Heloise Anne Pereira, Melva L. Gonzalez
-
Publication number: 20130195866Abstract: Disclosed herein are methods, and compositions for inhibiting neurodegeneration, e.g., in neuronal cells. The methods and compositions the invention can be used to treat a neurodegenerative disorder, e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, and frontotemproal dementia. In some embodiments, the methods and compositions can be used to inhibit neurodegeneration, e.g., caused by tau-mediated synaptic neurodegeneration, encephalitis, brain trauma, or any disorder suffering from weakening synapses.Type: ApplicationFiled: January 19, 2011Publication date: August 1, 2013Inventors: Brian J. Bacskai, Bradley T. Hyman, Kishore Kuchibhotla, Hai-Yan Wu
-
Patent number: 8496937Abstract: The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.Type: GrantFiled: March 30, 2010Date of Patent: July 30, 2013Assignees: Edimer Pharmaceuticals, Inc., Universite de LausanneInventors: Pascal Schneider, Nathalie Dunkel, Stephane Demotz
-
Publication number: 20130189260Abstract: There is provided antibodies or antigen-binding fragments thereof with binding specificity for ICAM-1, for use in the treatment of cancer in patients who have previously been treated for cancer and either not responded to said treatment or have previously responded to said treatment and subsequently relapsed.Type: ApplicationFiled: July 13, 2011Publication date: July 25, 2013Inventors: Markus Hansson, Bjorn Frendeus
-
Patent number: 8486395Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.Type: GrantFiled: November 19, 2012Date of Patent: July 16, 2013Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 8486409Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.Type: GrantFiled: April 20, 2010Date of Patent: July 16, 2013Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: David A. Scheinberg, Michael R. McDevitt, Dangshe Ma, George Sgouros
-
Patent number: 8481683Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.Type: GrantFiled: November 30, 2007Date of Patent: July 9, 2013Assignee: Medarex, Inc.Inventors: David John King, Alison Witte, Heidi N. LeBlanc, Richard Theolis, Asna Masood, Mark Yamanaka, Kyra D. Zens, Sarah R. Reed, Tim Sproul, Chetana Rao-Naik, David Passmore, Dawn M. Tanamachi, Kristopher Toy
-
Patent number: 8475793Abstract: The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders.Type: GrantFiled: February 6, 2009Date of Patent: July 2, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Rene De Waal Malefyt, Leonard G. Presta
-
Patent number: 8470978Abstract: Described are methods of separating viable cells, apoptotic cells and dead cells and antibodies or use in such methods. The antibodies may also be used in treatment of inflammatory disease, cancer and in wound healing.Type: GrantFiled: December 5, 2008Date of Patent: June 25, 2013Assignee: Grampian Biopartners LimitedInventor: Christopher Gregory
-
Patent number: 8470326Abstract: The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.Type: GrantFiled: January 21, 2011Date of Patent: June 25, 2013Assignee: Precision BiologicsInventors: Myron Arlen, Kwong Tsang
-
Publication number: 20130156787Abstract: The present invention relates to a pharmaceutical composition for promoting angiogenesis, containing an antibody that specifically binds to heat shock protein (HSP) 27. In addition, the present invention relates to a pharmaceutical composition containing an antibody that specifically binds to HSP 27, for treating an angiogenesis-dependent ailment selected from a group consisting of a wound, chronic ulcer, ischemic stroke, myocardial infarction, angina pectoris, and cerebrovascular dementia. In addition, the present invention relates to a method for promoting the in vitro growth of endothelial cells using an antibody that specifically binds to HSP27.Type: ApplicationFiled: August 18, 2011Publication date: June 20, 2013Applicant: Korea Institute of Radiological and Medical SciencesInventors: Yoon Jin Lee, Yun-Sil Lee, Hae-June Lee, Seo-Hyun Choi, Kyeng-Jung Kim
-
Patent number: 8461304Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: June 9, 2010Date of Patent: June 11, 2013Assignee: Affitech Research ASInventors: Lavinia Diana Cicortas Gunnarsson, Didrik Paus
-
Publication number: 20130142810Abstract: Provided herein are methods for inhibiting tumor angiogenesis in a cancer patient, the method comprising administering to the subject an effective amount of a first isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) and an effective amount of a second isolated binding molecule which specifically binds to VEGF.Type: ApplicationFiled: December 6, 2012Publication date: June 6, 2013Applicant: Vaccinex, Inc.Inventor: Vaccinex, Inc.
-
Patent number: 8455622Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.Type: GrantFiled: December 1, 2007Date of Patent: June 4, 2013Assignee: Seattle Genetics, Inc.Inventors: Charlotte McDonagh, Paul Carter, Django Sussman
-
Patent number: 8454958Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with specific binding of the ?5?1 integrin to a ligand expressed in the tissue. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of ?5?1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of ?5?1 integrin to a ligand in a tissue associated with the pathological condition.Type: GrantFiled: December 7, 2011Date of Patent: June 4, 2013Assignee: The Regents of the University of CaliforniaInventor: Judith A. Varner
-
Publication number: 20130129744Abstract: An antibody for activating plasminogen is provided. The antibody is produced from a hybridoma cell line deposited on Nov. 24, 2011 under accession number BCRC 960433 at Food Industry Research and Development Institute, 331 Shih-Pin Road, Hsinchu 300, Taiwan. The uses and producing method of the antibody, and an agent including the antibody used for treating stroke, myocardial infarction or syndromes cause by thrombus are also disclosed.Type: ApplicationFiled: November 2, 2012Publication date: May 23, 2013Applicant: NATIONAL CHENG KUNG UNIVERSITYInventor: National Cheng Kung University
-
Patent number: 8444977Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.Type: GrantFiled: July 12, 2010Date of Patent: May 21, 2013Assignees: Eli Lilly and Company, Washington UniversityInventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
-
Patent number: 8444983Abstract: The present invention provides antibodies or antigen-binding fragments thereof that specifically bind the ENDO180 polypeptide and are internalized thereby, to conjugates comprising the molecules, to compositions comprising the antibodies and conjugates and to methods of using the same for delivery of therapeutic agents to cells that express the ENDO180 polypeptide on the surface of the cell for treating cell proliferative diseases or disorders and fibrosis, and for controlling (modulating) tumor progression.Type: GrantFiled: March 23, 2010Date of Patent: May 21, 2013Assignee: Quark Pharmaceuticals, Inc.Inventor: Elena Feinstein
-
Patent number: 8445645Abstract: The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.Type: GrantFiled: June 10, 2011Date of Patent: May 21, 2013Assignee: MacroGenics, Inc.Inventors: Jeffrey Stavenhagen, Sujata Vijh, Christopher Rankin, Sergey Gorlatov, Ling Huang
-
Patent number: 8425910Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody.Type: GrantFiled: September 23, 2011Date of Patent: April 23, 2013Assignee: Biogen Idec MA Inc.Inventors: Sha Mi, R. Blake Pepinsky, Christilyn Graff
-
Patent number: 8425912Abstract: The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate.Type: GrantFiled: August 15, 2012Date of Patent: April 23, 2013Assignee: Immunomedics, Inc.Inventor: Serengulam V. Govindan
-
Patent number: 8425907Abstract: The present invention provides methods for treating pruritus by blocking human protease activated receptor-2 (PAR2) activity. The methods of the invention can be used to treat pruritus associated with atopic dermatitis, psoriasis, burn scarring, hypertrophic scarring, keloids, renal failure or hepatic failure. The methods of the invention include administering an antibody or antigen-binding fragment thereof that specifically binds human PAR2.Type: GrantFiled: December 14, 2011Date of Patent: April 23, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Andrew J. Murphy, Nicholas J. Papadopoulos, Marc R. Morra, Robert R. Salzler, Michael L. LaCroix-Fralish
-
Patent number: 8425905Abstract: Monoclonal antibody 9TL and antibodies derived from 9TL directed against amyloid-beta peptide and methods of using same for diagnosing and treatment of Alzheimer's disease and A? peptide associated diseases are described. Methods of using antibodies directed against amyloid-beta peptide having impaired effector function for treatment of Alzheimer's disease and A? peptide associated diseases are also described.Type: GrantFiled: July 5, 2012Date of Patent: April 23, 2013Assignee: Rinat Neuroscience Corp.Inventors: Arnon Rosenthal, Jaume Pons, Wei-Hsien Ho, Jan Markus Grimm
-
Publication number: 20130095114Abstract: Combinations of anti-cancer vaccines and inhibitory antibodies to CD223 overcome immune suppression in cancer patients. The vaccines may be isolated antigens, groups of antigens, or whole tumor cells. The inhibitory antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.Type: ApplicationFiled: November 16, 2012Publication date: April 18, 2013Applicants: ST. JUDE CHILDREN'S RESEARCH HOSPITAL INC., THE JOHNS HOPKINS UNIVERSITYInventors: The Johns Hopkins University, St. Jude Children's Research Hospital Inc.
-
Publication number: 20130095118Abstract: Provided herein are methods for decreasing blood-brain barrier permeability in a subject with a neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.Type: ApplicationFiled: October 11, 2012Publication date: April 18, 2013Applicant: Vaccinex, Inc.Inventor: Vaccinex, Inc.
-
Publication number: 20130084293Abstract: Methods of treating a food allergy, allergic reactions, hypersensitivity, inflammatory responses, inflammation are provided. In one method, histamine releasing factor (HRF)/translationally controlled tumor protein (TCTP) is contacted with a compound that inhibits or reduces binding of HRF/TCTP to an immunoglobulin in order to treat the food allergy, allergic reaction, hypersensitivity, inflammatory response, or inflammation. Methods of reducing or decreasing the probability, severity, frequency, duration or preventing a subject from having an acute or chronic food allergy, allergic reaction, hypersensitivity, an inflammatory response or inflammation, are also provided.Type: ApplicationFiled: September 28, 2012Publication date: April 4, 2013Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGYInventor: LA JOLLA INSTITUTE FOR ALLERGY AND IMMU
-
Patent number: 8409572Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic purpura (ITP).Type: GrantFiled: March 30, 2012Date of Patent: April 2, 2013Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
-
Patent number: 8404233Abstract: The present invention provides a binding protein capable of binding to delta-like ligand 4 (DLL4) as well as methods and uses thereof in therapy, diagnosis or imaging. Also provided are fusion proteins and protein conjugates, nucleic acid molecules encoding the binding proteins and methods of preparing binding proteins capable of binding to DLL4.Type: GrantFiled: May 15, 2008Date of Patent: March 26, 2013Assignee: Smart Targeting LimitedInventors: Makoto Sunamura, Hideo Yagita
-
Patent number: 8399618Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.Type: GrantFiled: December 23, 2011Date of Patent: March 19, 2013Assignee: Xencor, Inc.Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
-
Patent number: 8398978Abstract: Methods of using antibodies directed to the C-terminal side of ?-amyloid peptide for diagnosing and treatment of Alzheimer's disease and A? peptide associated diseases are described.Type: GrantFiled: March 15, 2010Date of Patent: March 19, 2013Assignee: Rinat Neuroscience Corp.Inventors: Arnon Rosenthal, Jaume Pons, Wei-Hsien Ho
-
Publication number: 20130064860Abstract: The invention provides a pharmaceutical composition comprising a) an activated-potentiated form of an antibody to prostate-specific antigen, and b) an activated-potentiated form of an antibody to endothelial NO-synthase. Various embodiments and variants are provided. The invention provides methods of treating benign prostatic hyperplasia and erectile dysfunctions and various methods of administration comprising administering a pharmaceutical composition comprising a) an activated-potentiated form of an antibody to prostate-specific antigen, and b) an activated-potentiated form of an antibody to endothelial NO-synthase.Type: ApplicationFiled: July 15, 2011Publication date: March 14, 2013Inventor: Oleg Iliich Epshtein
-
Patent number: 8394925Abstract: The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.Type: GrantFiled: December 15, 2011Date of Patent: March 12, 2013Assignee: Xencor, Inc.Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
-
Publication number: 20130058982Abstract: The present invention relates to a method of treating Alzheimer's disease by administration of activated-potentiated form of antibodies to brain-specific protein S-100 and activated-potentiated form of antibodies to endothelial NO synthase.Type: ApplicationFiled: July 15, 2011Publication date: March 7, 2013Inventor: Oleg Iliich Epshtein
-
Patent number: 8388957Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-1R kinase inhibitors. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methodology are also provided.Type: GrantFiled: November 11, 2011Date of Patent: March 5, 2013Assignee: OSI Pharmaceuticals, LLCInventor: John D. Haley
-
Patent number: RE44389Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: October 17, 2012Date of Patent: July 23, 2013Assignee: Hoffman-La Roche Inc.Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Braemer, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt